Pasithea Therapeutics Corp. (KTTA) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.44

From 52W high−71.95%

Volume18366.00

Market cap$13.78M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$0.44

From 52W high

−71.95%

Volume

18366.00

Market cap

$13.78M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.4x

P/E (TTM)

—

RSI (14)

34.7

MomentumView details →

1D Return

−1.83%

YTD Return

−67.45%

SummaryUpdated Jun 1, 2026

Pasithea Therapeutics Corp. (NASDAQ:KTTA) is a clinical-stage biotechnology company founded in 2020 and headquartered in Miami Beach, Florida. The company went public in September 2021 and focuses on developing treatments for psychiatric and neurological disorders. Pasithea operates as a pre-revenue biotech company conducting research and discovery activities while also planning to establish anti-depression treatment clinics that would offer ketamine infusion therapies administered by trained pharmacists.

Ask drillr about Pasithea Therapeutics Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

1.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−42.72%

ROA (TTM)

−41.18%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+74.59%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+77.07%

EBITDA YoY

−78.91%

MomentumView details →

1D Return

−1.83%

YTD Return

−67.45%

1Y Return

−43.82%

RSI (14)

34.7

vs 50D SMA

−16.13%

vs 200D SMA

−36.18%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

26.25x

Quick Ratio

26.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.16

EPS Surprise

0.00%

Beats (12Q)

2/12

Next Q EPS Est

−$0.25

Avg Surprise (4Q)

−76.46%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−21.29M

Op. CF (TTM)

−17.78M

Next earningsNov 12, 2026 →

Latest newsMore news →

The FDA granted Orphan Drug Designation to Pasithea Therapeutics' PAS-004 for the treatment of ALS.139d ago

Similar companies

Daré Bioscience, Inc.DARE Allarity Therapeutics, Inc.ALLR BioCardia, Inc.BCDA Actuate Therapeutics IncACTU Radiopharm Theranostics LimitedRADX TScan Therapeutics, Inc.TCRX Find similar companies →

Latest newsMore news →

Pasithea Therapeutics announced it will present initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with NF1 at the 2026 European Neurofibromatosis Conference in Vienna, Austria, on November 12-14, 2026.35d ago The FDA granted Orphan Drug Designation to Pasithea Therapeutics' PAS-004 for the treatment of ALS.139d ago